Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming when stakes are high
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
February 2, 2026
Hematology Today—February 2, 2026
February 1, 2026
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission
January 30, 2026
Public Health Video Recap—January 30, 2026
January 30, 2026
Public Health Today—30 January, 2026
January 30, 2026
Vaccines Today—January 30, 2026
January 30, 2026
Respiratory Today—January 30, 2026
January 29, 2026
Rare Disease Video Recap—January 29, 2026
January 29, 2026
Cardiovascular Video Recap—January 29, 2026
January 29, 2026